Marker Therapeutics (MRKR) has released an update.
Marker Therapeutics has been granted $2 million by the NIH to further its Phase 1 study on MT-601 for patients with relapsed non-Hodgkin’s lymphoma post CAR-T therapy. The company is optimistic about the potential of MT-601, as early results show promise without severe side effects. This grant signifies NIH’s recognition of the study’s scientific merit and its role in addressing a current medical need.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
